A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis
Latest Information Update: 17 Apr 2025
At a glance
- Drugs INT-787 (Primary)
- Indications Alcoholic hepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms FRESH
- Sponsors Intercept Pharmaceuticals
Most Recent Events
- 09 Apr 2025 Planned number of patients changed from 50 to 80.
- 09 Apr 2025 Planned End Date changed from 31 Mar 2025 to 1 Apr 2027.
- 09 Apr 2025 Planned primary completion date changed from 31 Dec 2024 to 6 Sep 2026.